Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.45 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.42 |
| ▸ | DPP3 | Q9NY33 | 5/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.40 |
| ▸ | CTSC | P53634 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14903396 | 1.00 | TACR1 (0.45) | TACR1CTRB1DPP3HRH4REN | |
| SCHEMBL18933192 | 0.92 | CTRB1 (0.42) | TACR1CTRB1RENNTMT1CTSC | |
| SCHEMBL14906464 | 0.91 | CTRB1 (0.48) | TACR1CTRB1RENCTSC | |
| SCHEMBL6878588 | 0.91 | CTRB1 (0.48) | TACR1CTRB1RENCTSC | |
| SCHEMBL6876603 | 0.91 | CTRB1 (0.48) | TACR1CTRB1RENCTSC | |
| SCHEMBL6880524 | 0.91 | CTRB1 (0.48) | TACR1CTRB1RENCTSC | |
| SCHEMBL6876472 | 0.91 | CTRB1 (0.48) | TACR1CTRB1RENCTSC | |
| SCHEMBL14906471 | 0.91 | CTRB1 (0.48) | TACR1CTRB1RENCTSC | |
| SCHEMBL6880238 | 0.90 | DPP3 (0.53) | TACR1DPP3OPRM1 | |
| SCHEMBL6877616 | 0.90 | DPP3 (0.53) | TACR1DPP3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170157204-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | LODZ UNIVERSITY OF TECHNOLOGY (PL) | 2017-06-08 | — | — | US | disclosed |
| US-20170157204-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | LODZ UNIVERSITY OF TECHNOLOGY (PL) | 2017-06-08 | — | — | US | disclosed |
| US-9382292-B2 | Cyclic tetrapeptides and therapeutic applications thereof | PEPTADERM SP. Z O.O. (PL) | 2016-07-05 | — | — | US | disclosed |
| US-9382292-B2 | Cyclic tetrapeptides and therapeutic applications thereof | PEPTADERM SP. Z O.O. (PL) | 2016-07-05 | — | — | US | disclosed |
| US-20130108655-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | PEPTADERM SP. Z O.O. (PL) | 2013-05-02 | — | — | US | disclosed |
| US-20130108655-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | PEPTADERM SP. Z O.O. (PL) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157204-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | PNISR, APLNR, VIP | TACR1 81/4885CTRB1 1251/4885DPP3 300/4885 |
| US-20130108655-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | PNISR, APLNR, VIP | TACR1 81/4885CTRB1 1251/4885DPP3 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.